A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.

Start Date21 Nov 2024

Sponsor / Collaborator

UCB Biopharma SRL

NCT04976322

/ Enrolling by invitationPhase 3

A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Dapirolizumab Pegol Treatment in Study Participants With Systemic Lupus Erythematosus

The purpose of this study is to evaluate long-term safety and tolerability of dapirolizumab pegol treatment.

Start Date27 Jul 2021

Sponsor / Collaborator

UCB Biopharma SRL

NCT04571424

/ CompletedPhase 1

Phase 1, Randomized, Blinded, Placebo-Controlled, Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Dapirolizumab Pegol (BIIB133) in Healthy Japanese and Caucasian Study Participants

The primary objective of the study is to assess the safety and tolerability of a single intravenous (IV) dose of dapirolizumab pegol (DZP) in Japanese healthy study participants compared with those of Caucasian healthy study participants.
The secondary objectives of the study are to assess the pharmacokinetic(s) (PK) of a single IV dose of DZP in Japanese and Caucasian healthy study participants, to evaluate ethnic sensitivity on the PK of DZP between body weight- and gender-matched Japanese and Caucasian healthy study participants and to evaluate the immunogenicity of a single IV dose of DZP in Japanese and Caucasian healthy study participants.

Start Date14 Oct 2020

Sponsor / Collaborator

Biogen, Inc.

100 Clinical Results associated with Dapirolizumab pegol

100 Translational Medicine associated with Dapirolizumab pegol

100 Patents (Medical) associated with Dapirolizumab pegol

444

Literatures (Medical) associated with Dapirolizumab pegol

01 Jun 2026·CNS & Neurological Disorders-Drug Targets

Putative Antianxiety Property of Oral Enalapril Formulation in Mice: a Preclinical and in silico Study

Article

Author: da Silva Pinheiro, Denise ; Aprigliano, Vicente ; Costa, Rafael Fernandes ; Napolitano, Hamilton Barbosa ; Martins, Jose Luis Rodrigues ; da Silva-Junior, Edeildo Ferreira ; de Aguiar, Antonio Sergio Nakao ; Sa Filho, Alberto Souza ; Machado, Sergio ; Fajemiroye, James Oluwagbamigbe ; Padilha, Emanuelly Karla Araujo ; Rodrigues, Gustavo Pedrino

Introduction::

Anxiety disorders, characterized by overwhelming fear, affect more than 30% of the global population. Recent evidence indicates that antihypertensive medications could offer symptomatic relief for anxiety, supporting their potential for repurposing. The objective is to investigate the anxiolytic-like effects of an enalapril formulation.

Methods::

60 Swiss mice (30 ± 5 g, aged 6-8 weeks) were randomly assigned to groups and received oral treatments with either vehicle (10 mL/kg), diazepam (DZP, 5 mg/kg), reference enalapril (ENAR), enalapril formulation (ENAF), losartan (LOS), or propranolol (PRO), each at a dose of 10 mg/kg. After 60 minutes, the animals were exposed to 5 minutes of exploratory activity in the open field, elevated plus maze (EPM), light-dark box (LDB), and a minute of rotarod.

Results::

One-way ANOVA demonstrated differences for the total crossing (p=0.0001), freezing time (p=0.0001), number of rearing (p=0.002), time spent (p=0.002), and crossing at the center (p=0.0001) of the open field. Unlike in the rotarod (p>0.05), the ENAR, ENAF, LOS, and PRO elicit increases (p<0.05) in the total number of arm entries and time spent on the open arms of EPM while increasing the number of transitions (p<0.05) and time spent in the light area of the LDB (p=0.001). In silico screening suggests stability of interaction with several amino acid residues overlapping with the flumazenil binding site, with the binding energy (ΔE) = −22.59kcal/mol towards the benzodiazepine binding site (flumazenil ΔE = −43.92kcal/mol).

Discussion::

The repositioning of drugs available to the population is an interesting approach toward the discovery of alternative or add-on treatments for anxiety. Ongoing resort to repurposing, reusing, reprofiling, and rediscovery of “old” drugs for a new indication seems to be an interesting way out of failures, the expensive and slow pace of new drug discovery.

Conclusion::

Enalapril demonstrates anxiolytic-like properties, further insights into the GABAergicrenin- angiotensin-aldosterone mechanistic hypothesis.

01 May 2026·JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS

Pharmacokinetics and Residue Elimination of Diazepam in Zebrafish

Article

Author: Li, Ting‐Ting ; Li, Si‐Ting ; Liao, Xiao‐Ping ; Zhao, Dong‐Hao ; Xiao, Hong‐Liang ; Xin, Lin

ABSTRACT:

Diazepam (DZP) residues in aquaculture environments pose a serious threat to food safety. To investigate the pharmacokinetics and residue elimination patterns of DZP using zebrafish as a model organism, a pharmacokinetic study, zebrafish were exposed to 1 mg/L DZP via bath for 24 h. DZP was metabolized to nordiazepam (NDZP), oxazepam (OZP), and temazepam (TZP). Non‐compartmental analysis yielded the following pharmacokinetic parameters: T1/2 = 4.25–11.78 h; MRT = 3.52–7 h; AUC = 34.51–4222.69 h·μg/kg; Vd = 1.16–6.15 L/kg; CL = 0.14–0.57 L/h/kg. The results indicate that DZP and its metabolites are rapidly absorbed and widely distributed in zebrafish, but eliminated slowly. For the residue elimination study, OZP fell below the LOD (0.05 μg/kg) after 40 days; NDZP and TZP were undetectable after 60 days. DZP persisted at 0.54 ± 0.2 μg/kg on day 150, confirming exceptionally slow elimination. The findings are expected to fill a critical data gap concerning the pharmacokinetics and residue elimination of DZP in zebrafish. These findings provide a framework for extending the results to similar rare edible small fish, thereby aiding in food safety assessment and risk management.

01 May 2026·NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Sedative effects of physcion and its modulatory interaction with diazepam: in vivo and in silico evaluation

Article

Author: Islam, Muhammad Torequl ; Altemani, Abdullah H ; Altemani, Faisal H ; Bhuia, Md Shimul ; Shadin, Md ; Alsenani, Faisal ; Alfaifi, Mohammed ; Chowdhury, Raihan

Physcion (PHY), an anthraquinone derivative, has demonstrated various biological properties, including antioxidant and anti-inflammatory effects. This study aimed to evaluate the sedative activity of PHY in Swiss mice using in vivo and in silico approaches. The thiopental sodium (TS)-induced sleep model, fireplace test, and hole cross test were employed to assess sedation along with molecular docking studies. PHY significantly (p < 0.05) reduced sleep latency (17.29 ± 2.33 min) and increased sleep duration (162.85 ± 8.38 min) compared to controls at higher doses. It also significantly increased (p < 0.05) jump time and decreased the number of hole crosses. Co-administration of PHY with diazepam (DZP) enhanced sedation, while Co-administration with flumazenil (FLN) attenuated it, suggesting modulation of GABA_A receptors. In silico molecular docking revealed a strong binding affinity (- 8.1 kcal/mol) of PHY with GABA_A receptor subunits α1 and β2, comparable to DZP. Pharmacokinetic and toxicity predictions showed favorable profiles, supporting the potential of PHY as a sedative agent. Overall, PHY exhibited significant sedative effects likely mediated through the GABAergic pathway.

News (Medical) associated with Dapirolizumab pegol

04 Jun 2026

·www.biospace.com

EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

Steroid use reduction and disease control: In additional results from the Phase 3 PHOENYCS GO study, dapirolizumab pegol (DZP) plus standard of care was associated with sustained disease control at lower glucocorticoid doses through Week 48 compared with placebo plus standard of care, supporting reduced long-term steroid exposure Reduced flare rates and immune marker improvements: In other findings presented at EULAR 2026, improvements in immunological markers and reduced flare rates were observed, supporting the potential of dapirolizumab pegol to address the complex burden of SLE BRUSSELS, Belgium and CAMBRIDGE, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) today announced data, comprising two posters and three abstracts, at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, demonstrating the clinical pro dapirolizumab pegol (DZP), an investigational biologic in patients with systemic lupus erythematosus (SLE). Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting multiple organs, including skin, joints and kidneys, often requiring long-term treatment to control disease activity. 1 Patients with SLE frequently experience flares, transient worsening of disease activity that can lead to permanent organ damage, increased morbidity, and even early mortality. 2 Many patients rely on steroid-based therapy to manage flares; however, prolonged steroid use is associated with significant cumulative toxicity, making steroid tapering while maintaining disease control a key goal in SLE management. 3,4 “Achieving and maintaining durable disease control while reducing glucocorticoid exposure is one of the central challenges in managing SLE,” said Megan E. B. Clowse, M.D., MPH, Chief of the Division of Rheumatology and Immunology, Duke University, and primary author of the PHOENYCS GO primary results. “The Phase 3 PHOENYCS GO data showed patients receiving dapirolizumab pegol were more likely to maintain disease control while tapering steroids – an important finding given strong evidence that cumulative steroid exposure and uncontrolled disease activity are major drivers of organ damage accrual, morbidity and mortality in SLE.” Post hoc analyses displayed in one of the posters from the PHOENYCS GO program showed that, in patients with baseline glucocorticoid dose >7.5 mg/day prednisone equivalent, treatment with DZP plus standard of care was associated with a higher proportion of patients achieving control of disease activity while enabling glucocorticoid tapering to ≤7.5 mg/day through Week 48, compared with placebo plus standard of care. 5 Importantly, these findings suggest that higher proportions of patients receiving DZP plus standard of care versus placebo plus standard of care achieved sustained glucocorticoid tapering while also achieving BICLA response, achieving SRI-4 response, or remaining free from moderate or severe BILAG-2004 flares through Week 48. 5 “At UCB, our mission is to help improve the lives of people living with serious inflammatory diseases by advancing therapies that address unmet needs,” said Donatello Crocetta, Chief Medical Officer and Head of Global Medical Affairs at UCB. “These data showed the potential of dapirolizumab pegol to reduce long-term glucocorticoid use while maintaining disease control, an important goal for people living with SLE and the clinicians who care for them.” Additional EULAR 2026 presentations highlighted the breadth of data from the PHOENYCS GO program, including: Improvements in key immunological markers, including reduced anti-dsDNA antibodies and increased complement proteins C3 and C4 in patients with abnormal levels at baseline (Poster POS1364). 6 Lower rates of moderate or moderate/severe BILAG-2004 flares with DZP plus standard of care versus placebo plus standard of care through Week 48, using alternative definitions of flares to increase measurement sensitivity (Abstract AB1163). 7 Insights into how symptoms and flares are assessed in SLE, including fatigue as a burdensome patient-reported symptom that can be difficult to capture in clinical trials (Abstracts AB1184 and AB1125). 8,9 Together, these findings support the importance of tools that can measure patient experience and help inform more meaningful assessment of disease impact in both clinical practice and research. 8,9 “Systemic lupus erythematosus is a biologically complex disease, and these EULAR data further characterize dapirolizumab pegol’s impact across clinical, biological and patient-reported outcomes,” said Diana Gallagher, MD, Head of Immunology, MS and Alzheimer’s Development Units at Biogen. “Delivering this data reflects the strength of the UCB and Biogen collaboration and our shared commitment to advancing evidence that may help address the complex and multifaceted needs of people living with SLE.” The EULAR data follow the recent publication of the Phase 3 PHOENYCS GO study in The Lancet , reporting clinically meaningful improvements in disease activity with dapirolizumab pegol at Week 48. 10 In the Phase 3 PHOENYCS GO study, DZP demonstrated a generally favorable safety profile, with safety findings consistent with previous DZP studies. 10,11 Treatment-emergent adverse events were more common with DZP plus standard of care versus placebo plus standard of care, while serious treatment-emergent adverse events were less frequent in the DZP plus standard of care arm, and discontinuations due to treatment-emergent adverse events were low in both groups. 10 About Dapirolizumab Pegol Dapirolizumab pegol is a novel investigational humanized Fc-free polyethylene glycol (PEG)-conjugated antigen-binding (Fab’) fragment. 11 Dapirolizumab pegol inhibits CD40L signaling, which has been shown to reduce B-cell activation and autoantibody production, mitigate type 1 interferon (IFN) secretion and attenuate T-cell and antigen-presenting cell (APC) activation. 11 Dapirolizumab pegol is presently in Phase 3 clinical development for the treatment of systemic lupus erythematosus (SLE) under a collaboration between UCB and Biogen. 12,13 Dapirolizumab pegol is an investigational biologic currently in clinical development. The safety and efficacy have not been established, and it is not approved by any health authority worldwide. About UCB UCB, Brussels, Belgium ( ), is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 9,000 people in approximately 40 countries, the company generated revenue of €7.7 billion in 2025. UCB is listed on Euronext Brussels (symbol: UCB). About Biogen Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient’s lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth. We routinely post information that may be important to investors on our website at . Follow us on social media - Facebook , LinkedIn , X , YouTube . Forward-looking Statements - UCB This document contains forward-looking statements, including, without limitation, statements containing the words “potential”, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “continue” and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guaranteeing future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this document. Important factors that could result in such differences include but are not limited to: global spread and impacts of wars, pandemics and terrorism, the general geopolitical environment, climate change, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues, supply chain disruption and business continuity risks; potential or actual data security and data privacy breaches, or disruptions of UCB’s information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars or disruptive technologies/business models, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in laws and/or rules pertaining to tax and duties or the administration of such laws and/or rules, and hiring, retention and compliance of employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB’s efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB’s products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB’s data and systems. Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this document, and do not reflect any potential impacts from the evolving event or risk as mentioned above as well as any other adversity, unless indicated otherwise. The company continues to follow the development diligently to assess the financial significance of these events, as the case may be, to UCB. UCB expressly disclaims any obligation to update any forward-looking statements in this document, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations. Biogen Safe Harbor This news release contains forward-looking statements, including, among others, relating to: the potential benefits, safety and efficacy of dapirolizumab pegol (DZP); the potential of dapirolizumab pegol to address the needs of people living with systemic lupus erythematosus (SLE), including the potential to help patients maintain disease control while tapering steroids; the anticipated benefits, risks and potential of Biogen's collaboration arrangements with UCB; the potential of Biogen's commercial business and pipeline programs, including dapirolizumab pegol; potential regulatory discussions, submissions and approvals and the timing thereof; and the risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “hope,” “intend,” “may,” “objective,” “outlook,” “plan,” “possible,” “potential,” “predict,” “project,” “prospect,” “should,” “target,” “will,” “would,” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements. These forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to be materially different from those stated or implied in this document, including, among others, factors relating to: uncertainty of our long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans, prospects and timing of actions relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product competition in the biopharmaceutical and healthcare industry, as well as any other markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways; our ability to effectively implement our corporate strategy; difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products; the drivers for growing our business, including our dependence on collaborators and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control; risks related to commercialization of biosimilars, which is subject to such risks related to our reliance on third-parties, intellectual property, competitive and market challenges and regulatory compliance; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; and the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at These statements speak only as of the date of this presentation and the discussions during this conference call and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in our subsequent reports on Form 10-Q. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise. Biogen Digital Media Disclosure From time to time, we have used, or expect in the future to use, our investor relations website (investors.biogen.com), the Biogen LinkedIn account (linkedin.com/company/biogen-) and the Biogen X account ( ) as a means of disclosing information to the public in a broad, non-exclusionary manner, including for purposes of the SEC’s Regulation Fair Disclosure (Reg FD). Accordingly, investors should monitor our investor relations website and these social media channels in addition to our press releases, SEC filings, public conference calls and websites, as the information posted on them could be material to investors. References: Pons-Estel GJ, Alarcón GS, Scofield L, et al. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum. 2010;39(4):257-68. Thanou A, Jupe E, Purushothaman M, et al. Clinical disease activity and flare in SLE: current concepts and novel biomarkers. J Autoimmun. 2021;119:102615. doi:10.1016/j.jaut.2021.102615. Palmowski A, Pankow A, Terziyska K, et al. Continuing versus tapering low-dose glucocorticoids in patients with rheumatoid arthritis and systemic lupus erythematosus in states of low disease activity or remission: a systematic review and meta-analysis of randomised trials. Semin Arthritis Rheum. 2024;64:152349. doi:10.1016/j.semarthrit.2023.152349. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–45. doi:10.1136/annrheumdis-2019-215089. Morand EF, Bertsias G, Carter LM, et al. Glucocorticoid-sparing maintenance of disease control in patients with systemic lupus erythematosus: 48-week results from a phase 3 trial of dapirolizumab pegol. Ann Rheum Dis. 2026;85(Suppl 1):POS0730. Dörner T, Pisetsky DS, Fava A, et al. Dapirolizumab pegol treatment and improvement in laboratory markers of disease activity in patients with systemic lupus erythematosus: 48-week results from a phase 3 trial. Ann Rheum Dis. 2026;85(Suppl 1):POS1364. Furie RA, Bertsias G, Carter LM, et al. Dapirolizumab pegol and flare reduction in patients with systemic lupus erythematosus in a 48-week phase 3 trial: an updated post hoc analysis of alternative definitions of flares that reflect clinical practice. Ann Rheum Dis. 2026;85(Suppl 1):AB1163. de la Loge C, Touma Z, Gordon C, et al. Measuring fatigue in systemic lupus erythematosus: measurement properties of the FATIGUE-PRO total score using data from a phase 3 trial of dapirolizumab pegol. Ann Rheum Dis. 2026;85(Suppl 1):AB1184. Mosca M, Anjohrin S, Rawlings A, et al. Physicians’ perspectives on recognition of flares in patients with systemic lupus erythematosus in the clinic: real world insights from the United States and Europe. Ann Rheum Dis. 2026;85(Suppl 1):AB1125. Clowse MEB, Isenberg DA, Merrill JT, et al. Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet . Published online May 29, 2026. doi:10.1016/S0140-6736(26)00691-4. Furie RA, Bruce IN, Dörner T, et al. Phase 2 randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate to severe active systemic lupus erythematosus (SLE). Rheumatology (Oxford). 2021;60(11): 5397-407. ClinicalTrials.gov. NCT04294667. . Accessed May 29, 2026. ClinicalTrials.gov. NCT06617325. . Accessed May 29, 2026. MEDIA CONTACT: UCB Adriaan Snauwaert +32 497 70 23 46 Adriaan.snauwaert@ucb.com CORPORATE COMMUNICATIONS UCB Laurent Schots +32 2 559 92 6 Laurent.schots@ucb.com Biogen Madeleine Shin + 1 781 464 3260 public.affairs@biogen.com INVESTOR CONTACT: UCB Yvonne Naughton +44 175 344 7521 Yvonne.Naughton@ucb.com Biogen Tim Power + 1 781 464 2442 IR@biogen.com

01 Jun 2026

·www.biospace.com

UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus

Publication adds to previously reported findings from Phase 3 PHOENYCS GO study, demonstrating statistically significant improvement in disease activity at Week 48 with dapirolizumab pegol plus standard of care versus placebo plus standard of care Findings showed results in favor of dapirolizumab pegol plus standard of care versus placebo plus standard of care across endpoints, including multiple disease activity measures, severe flares, patient-reported outcomes, including fatigue, and glucocorticoid tapering Results support the continued development of dapirolizumab pegol; the ongoing confirmatory Phase 3 PHOENYCS FLY clinical trial is currently recruiting BRUSSELS, Belgium and CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) today announced that The Lancet, a world-leading medical journal, has published the full results from the Phase 3 PHOENYCS GO clinical trial evaluating dapirolizumab pegol (DZP), an investigational, novel Fc-free CD40L inhibitor, in patients living with moderate-to-severe active systemic lupus erythematosus (SLE). The results showed statistically significant improvement in disease activity with DZP added to standard of care (SOC) versus placebo plus standard of care. 1 “The publication of the PHOENYCS GO results in The Lancet reflects the importance of these data to the rheumatology community, providing evidence of dapirolizumab pegol as a potential treatment option for people living with systemic lupus erythematosus,” said Megan E. B. Clowse, M.D., MPH, Chief of the Division of Rheumatology and Immunology, Duke University, and primary author of the publication. “Given the acute need for additional treatment options for SLE, these findings are encouraging for both clinicians and patients and clearly warrant further evaluation in the confirmatory Phase 3 PHOENYCS FLY study.” In the Phase 3 study, DZP successfully met the primary endpoint: a significantly greater proportion of patients receiving DZP plus standard of care (SOC) achieved British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) response at Week 48 (50%; 103/208) compared to placebo plus SOC (35%; 37/107; p=0.011). 1 BICLA is a composite endpoint measuring clinically relevant improvement of disease activity across all affected organ systems with no worsening in other lupus domains; a higher BICLA response rate reflects a treatment response and is associated with clinical benefit. 1 Because the first key secondary endpoint was not met (BICLA response at week 24), subsequent outcomes were not controlled for multiplicity. Results in favor of DZP plus SOC were observed across multiple outcomes, including severe BILAG flares, SRI-4, SLEDAI-2K, skin- and joint-related outcomes, and the serological markers anti-dsDNA antibodies and complement C3 and C4.¹ Additionally, at week 48 the data showed clinically meaningful improvements in patient-reported FACIT-Fatigue, which is often cited by patients as one of the most debilitating symptoms of SLE. 1,2 Importantly, these results were achieved within the context of glucocorticoid tapering in line with treatment guidelines. 1, 3 At week 48, a greater proportion of patients in the DZP plus SOC group versus PBO plus SOC were able to reduce their glucocorticoid dose from >7.5 mg/day to ≤7.5 mg/day, suggesting a glucocorticoid-sparing effect of DZP. 1 In the PHOENYCS GO study, DZP demonstrated a generally favorable safety profile, with safety findings consistent with previous DZP studies. 1, 4 Treatment-emergent adverse events (TEAEs) were more common with DZP plus SOC versus PBO plus SOC (82.6% [176/213] vs. 75.0% [81/108], respectively), while serious TEAEs were less frequent in the DZP plus SOC arm (10.0% [21/213] vs. 14.8% [16/108]) respectively. 1 Discontinuations due to TEAEs were low in both groups (4.7% vs. 3.7%) respectively. 1 These positive Phase 3 results support the continued development of DZP. UCB and Biogen are actively progressing the confirmatory Phase 3 PHOENYCS FLY clinical trial ( NCT06617325 ), which is currently recruiting patients and is intended to support future regulatory filings. 5 Further data from the PHOENYCS GO study will be presented this week at the Annual European Congress of Rheumatology (EULAR). About Dapirolizumab Pegol Dapirolizumab pegol is a novel investigational humanized Fc-free polyethylene glycol (PEG)-conjugated antigen-binding (Fab’) fragment. 4 Dapirolizumab pegol inhibits CD40L signaling which has been shown to reduce B-cell activation and autoantibody production, mitigate type 1 interferon (IFN) secretion and attenuate T-cell and antigen-presenting cell (APC) activation. 4 Dapirolizumab pegol is presently in Phase 3 clinical development for the treatment of systemic lupus erythematosus (SLE) under a collaboration between UCB and Biogen. 5 , 6 Dapirolizumab pegol is an investigational biologic currently in clinical development. The safety and efficacy have not been established, and it is not approved by any health authority worldwide. About UCB UCB, Brussels, Belgium ( ), is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 11,000 people in approximately 40 countries, the company generated revenue of €7.7 billion in 2025. UCB is listed on Euronext Brussels (symbol: UCB). About Biogen Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient’s lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth. We routinely post information that may be important to investors on our website at . Follow us on social media - Facebook , LinkedIn , X , YouTube . Forward-looking Statements - UCB This document contains forward-looking statements, including, without limitation, statements containing the words “potential”, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “continue” and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guaranteeing future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this document. Important factors that could result in such differences include but are not limited to: global spread and impacts of wars, pandemics and terrorism, the general geopolitical environment, climate change, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues, supply chain disruption and business continuity risks; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars or disruptive technologies/business models, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring, retention and compliance of its employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB’s efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB’s products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB’s data and systems. Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this document, and do not reflect any potential impacts from the evolving event or risk as mentioned above as well as any other adversity, unless indicated otherwise. The company continues to follow the development diligently to assess the financial significance of these events, as the case may be, to UCB. UCB expressly disclaims any obligation to update any forward-looking statements in this document, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations. Biogen Safe Harbor This news release contains forward-looking statements, including, among others, relating to: the potential benefits, safety and efficacy of dapirolizumab pegol (DZP); the potential of dapirolizumab pegol to be an important option in addressing the effects of systemic lupus erythematosus; the anticipated benefits, risks and potential of Biogen's collaboration arrangements with UCB; the potential of Biogen's commercial business and pipeline programs, including dapirolizumab pegol; potential regulatory discussions, submissions and approvals and the timing thereof; and the risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “hope,” “intend,” “may,” “objective,” “outlook,” “plan,” “possible,” “potential,” “predict,” “project,” “prospect,” “should,” “target,” “will,” “would,” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements. These forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to be materially different from those stated or implied in this document, including, among others, factors relating to: uncertainty of our long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans, prospects and timing of actions relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product competition in the biopharmaceutical and healthcare industry, as well as any other markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways; our ability to effectively implement our corporate strategy; difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products; the drivers for growing our business, including our dependence on collaborators and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control; risks related to commercialization of biosimilars, which is subject to such risks related to our reliance on third-parties, intellectual property, competitive and market challenges and regulatory compliance; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; and the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at These statements speak only as of the date of this presentation and the discussions during this conference call and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in our subsequent reports on Form 10-Q. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise. Biogen Digital Media Disclosure From time to time, we have used, or expect in the future to use, our investor relations website ( investors.biogen.com ), the Biogen LinkedIn account ( linkedin.com/company/biogen- ) and the Biogen X account ( ) as a means of disclosing information to the public in a broad, non-exclusionary manner, including for purposes of the SEC’s Regulation Fair Disclosure (Reg FD). Accordingly, investors should monitor our investor relations website and these social media channels in addition to our press releases, SEC filings, public conference calls and websites, as the information posted on them could be material to investors. References: Clowse MEB, Isenberg DA, Merrill JT, et al. Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet . Published online May 29, 2026. doi:10.1016/S0140-6736(26)00691-4. Cornet A, Andersen J, Myllys K, et al. Living with systemic lupus erythematosus in 2020: a European patient survey. Lupus Sci Med . 2021;8:e000469. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 2019; 78(6): 736–45. Furie RA, Bruce IN, Dörner T, et al. Phase 2 randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate to severe active systemic lupus erythematosus. Rheumatology (Oxford) . 2021;60(11):5397–407. ClinicalTrials.gov (NCT06617325). A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus (PHOENYCS FLY) 2024. Available at: . Retrieved May 18, 2026. ClinicalTrials.gov (NCT04294667). A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus (PHOENYCS GO) 2023. Available at: . Retrieved May 18, 2026. MEDIA CONTACT: UCB Adriaan Snauwaert +32 497 70 23 46 Adriaan.snauwaert@ucb.com Biogen Madeleine Shin + 1 781 464 3260 public.affairs@biogen.com INVESTOR CONTACT: UCB Yvonne Naughton +44 175 344 7521 Yvonne.Naughton@ucb.com Biogen Tim Power + 1 781 464 2442 IR@biogen.com

30 Mar 2026

·www.biospace.com

Biogen’s Lupus Drug Reduces Disease Activity, Further Deresking I&I Pipeline

iStock, Chee Siong Teh William Blair hailed a positive readout in cutaneous lupus erythematosus as a turning point for Biogen, while RBC Capital analysts called the results “another derisking step” for the company’s immunology and inflammation pipeline. Biogen’s litifilimab reduced disease activity in cutaneous lupus erythematosus in a second mid-stage study, providing another derisking step for the company’s immunology and inflammation (I&I) pipeline, according to analysts at RBC Capital Markets. “We believe this should underscore the promise of [Biogen’s] I&I pipeline,” the analysts said in a Sunday note to investors. Litifilimab—also known as liti—met the Phase 2/3 AMETHYST trial’s primary endpoint, showing an 11.8% higher reduction in disease activity in people with cutaneous lupus erythematosus (CLE) as measured by the Cutaneous Lupus Activity Investigators’ Global Assessment Revised (CLA-IGA-R) erythema score of 0-1 (clear/almost clear) at week 16 compared to placebo. Specifically, 14.7% of patients treated with liti achieved this target versus just 2.9% of patients on placebo, Biogen reported at the 2026 American Academy of Dermatology Annual Meeting on Saturday. Treatment with liti was also “associated with rapid and continued improvement in skin disease activity with separation from placebo observed as early as Week 4,” according to Biogen’s press release , with a score of 40.8% vs. 21.0% as measured by the Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity-50 (CLASI-50) through week 24. Notably, 16.3%—or 1 in 6—of liti recipients experienced no or minimal disease activity at week 24 compared to none of the placebo recipients. CLE is a serious autoimmune disease that causes skin rashes that can lead to permanent scarring and disfigurement, Diana Gallagher, senior vice president of Biogen’s Multiple Sclerosis and Immunology Disease Unit and Alzheimer’s and Dementia Disease Unit, told BioSpace. Diana Gallagher/ copyright David A. White AMETHYST’s results back an earlier successful Phase 2 trial, dubbed LILAC, in which liti showed a 22%–25% placebo-adjusted advantage at week 16 on the CLASI-50 in patients with CLE, according to RBC. The analysts called the drug’s consistent activity in this metric “encouraging.” Liti’s safety pro consistent with prior studies, Biogen reported. Next up in CLE, a one-year Phase 3 study is expected to produce topline data later next year, according to Gallagher. This trial will allow the company to “fully characterize safety and tolerability, time to effect and durability,” she said, adding that these data will be important to global regulators as well as patients. If approved, liti would be the first targeted therapy for CLE, Biogen said Saturday, and the first “innovative therapy” for the disease in 70 years. A Homegrown Asset Biogen CEO Chris Viehbacher highlighted litifilimab , a humanized IgG1 monoclonal antibody targeting BDCA2, during the company’s fourth quarter 2025 call in February, as an asset due for a lot of data this year. Earnings Biogen’s ‘Bridge To Growth’ Cuts Through a Stacked Phase 3 Pipeline With Biogen’s multiple sclerosis portfolio facing more generic pressure than ever, the company is eyeing a busy late-stage pipeline and hunting for deals to build its return to growth. February 6, 2026 · 2 min read · Annalee Armstrong Read more Along with CLE, liti is also in two Phase 3 trials for systemic lupus erythematosus (SLE), with data expected in the fourth quarter. Of the two indications, William Blair sees the CLE indication as having the greatest probability of success “given the clinical data to date,” according to a Monday morning note. Liti is a homegrown molecule, Gallagher said, “in a pathway that we spent a lot of time systematically understanding the biology.” The drug targets BDCA2, a protein present in specific cells within the immune system, according to Biogen’s website . The company’s hypothesis is that an antibody against this protein can interrupt the production of interferons, inflammatory molecules that are increased and contribute to disease activity in people with lupus. Biogen’s three therapeutic pillars are neurology, rare disease and immunology, Gallagher told BioSpace in September 2025. In immunology, with its staple multiple sclerosis franchise under increasing pressure from declining sales , Biogen has turned attention to other diseases. This includes lupus, primary membranous nephropathy and immunoglobulin A nephropathy (IgAN), the latter two of which is being targeted with anti-CD38 antibody felzartamab in Phase 3 trials. Another drug, dapirolizumab pegol, is also in Phase 3 trials for SLE, giving Biogen multiple late-stage shots on goal in this indication. “We’re at this inflection point now,” Gallagher told BioSpace in September. “We’ve been working in lupus for almost the whole decade that I’ve been here but really are now at this really exciting point.” Immunology and inflammation Lupus Reveal Gives Investors a Peek at Biogen’s ‘Underappreciated’ Pipeline With two late-stage programs set to read out in the next 48 months, Biogen is translating its wealth of experience in multiple sclerosis to lupus—developing a pipeline BMO Capital Markets analysts called “thoughtful.” September 9, 2025 · 4 min read · Heather McKenzie Read more Gallagher wouldn’t commit to a timeframe for litifilimab’s commercialization in either CLE or SLE, “but we’re getting much closer,” she said. “I’ve been working on this program for probably over a decade, so to me, it feels like soon.” For RBC, the upcoming SLE readouts “[kick] off a series of potential value-creating catalysts over the next several years, which we believe remain underappreciated and could further the company’s turnaround and generate further share appreciation.” William Blair heralded the CLE readout as a major turning point for Biogen: “With ~415,000 CLE patients across major geographies and breakthrough therapy designation in hand, litifilimab represents an exciting jump into Biogen’s next-generation immunology program, which we expect to bolster its waning multiple sclerosis franchise as it continues to explore new growth opportunities.”

Clinical ResultPhase 3Phase 2

100 Deals associated with Dapirolizumab pegol

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB16131

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Systemic Lupus Erythematosus	Phase 3	United States	UCB Biopharma SRL	12 Aug 2020
Systemic Lupus Erythematosus	Phase 3	Argentina	UCB Biopharma SRL	12 Aug 2020
Systemic Lupus Erythematosus	Phase 3	Australia	UCB Biopharma SRL	12 Aug 2020
Systemic Lupus Erythematosus	Phase 3	Belgium	UCB Biopharma SRL	12 Aug 2020
Systemic Lupus Erythematosus	Phase 3	Bulgaria	UCB Biopharma SRL	12 Aug 2020
Systemic Lupus Erythematosus	Phase 3	Canada	UCB Biopharma SRL	12 Aug 2020
Systemic Lupus Erythematosus	Phase 3	Chile	UCB Biopharma SRL	12 Aug 2020
Systemic Lupus Erythematosus	Phase 3	Colombia	UCB Biopharma SRL	12 Aug 2020
Systemic Lupus Erythematosus	Phase 3	Czechia	UCB Biopharma SRL	12 Aug 2020
Systemic Lupus Erythematosus	Phase 3	Denmark	UCB Biopharma SRL	12 Aug 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04294667 (PHOENYCS GO, ACR2025)	Phase 3	Systemic Lupus Erythematosus	315	Dapirolizumab pegol+standard of care	ejjsmnivgc(iqcjeqxtka) = lcblhapoyi czmkvktsqd (gzezjxzicx ) View more	Positive	24 Oct 2025
				Placebo+standard of care	ejjsmnivgc(iqcjeqxtka) = eagblntobk czmkvktsqd (gzezjxzicx ) View more
NCT04294667 (PHOENYCS GO, ACR2025)	Phase 3	Systemic Lupus Erythematosus	315	Dapirolizumab pegol+Standard of Care	dsneihksxt(ztpqnugbzo) = xhvwukster cyaeuxriak (nogoyhtrrj ) View more	Positive	24 Oct 2025
				Placebo+Standard of Care	dsneihksxt(ztpqnugbzo) = rsdbsqezqq cyaeuxriak (nogoyhtrrj ) View more
NCT04294667 (PHOENYCS GO, EULAR2025)	Phase 3	Systemic Lupus Erythematosus	315	Dapirolizumab pegol + Standard of Care	ueqemluamr(bambczkbmk) = bggpbfdgqp rsynchhipq (cfabivlmrn ) View more	Positive	11 Jun 2025
				Placebo + Standard of Care	ueqemluamr(bambczkbmk) = uwnlnhwyeq rsynchhipq (cfabivlmrn ) View more
NCT04294667 (PHOENYCS GO, EULAR2025)	Phase 3	Systemic Lupus Erythematosus	315	Dapirolizumab pegol+Standard of Care	armhxdyyrh(vpliksylvb) = qggcchvosa ckzclhgbbi (zchtrvoadr ) View more	Positive	11 Jun 2025
				Placebo+Standard of Care	armhxdyyrh(vpliksylvb) = owsabjgtqv ckzclhgbbi (zchtrvoadr ) View more
NCT04294667 (PHOENYCS GO, CTgov)	Phase 3	Systemic Lupus Erythematosus	321	placebo (PBO) (PBO+SOC)	ituxvwnxxz = yljumppsfn hnqkrjhmmi (pardlnomzk, wrdjowgxqx - xojucgxepl) View more	-	24 Apr 2025
				DZP (DZP+SOC)	ituxvwnxxz = ndxmufhsmp hnqkrjhmmi (pardlnomzk, jaonjhsszv - epvojutjqt) View more
NCT04294667 (PHOENYCS GO, ACR2024) Manual	Phase 3	Systemic Lupus Erythematosus	315	Dapirolizumab pegol + SOC	qyqvscvblf(nsjoxtgcso) = imurigzxwg aoiorrwoha (wksfnrbztp ) Met View more	Positive	24 Oct 2024
				Placebo+SOC	qyqvscvblf(nsjoxtgcso) = gfwrgsyvon aoiorrwoha (wksfnrbztp ) Met View more
NCT04294667 (PHOENYCS GO, NEWS) Manual	Phase 3	Systemic Lupus Erythematosus	321	dapirolizumab pegol	efspycdhtg(wzxdutnynp) = The trial achieved its primary endpoint. occnyyhdju (sfzhsargoz ) Met View more	Positive	24 Sep 2024
NCT02804763 (Pubmed) Manual	Phase 2	Systemic Lupus Erythematosus	-	PBO+SOC	pifoxdpsaw(angypgmhhr) = efugduhdmd kdmukvmljf (rkjnvjskad ) Not Met View more	Negative	03 Nov 2021
				dapirolizumab pegol 6 mg/kg+SOC	pifoxdpsaw(angypgmhhr) = bsdnwsfbdg kdmukvmljf (rkjnvjskad ) Not Met View more
NCT02804763 (RISE, CTgov)	Phase 2	Systemic Lupus Erythematosus	182	Placebo (SOC + Placebo iv Q4W (FAS))	zadauujzno = uevphupkml hxmsizndol (kuhglrvkqn, ygzniyojxr - wfnnbcledh) View more	-	30 Jun 2021
				SOC+DZP (SOC + DZP 6mg/kg iv Q4W (FAS))	zadauujzno = lqsxxxpopa hxmsizndol (kuhglrvkqn, bpyywhqmkp - kpqqbirgjz) View more
NCT01764594 (Pubmed \| Arthritis Rheumatol) Manual	Phase 1	Systemic Lupus Erythematosus	24	dapirolizumab pegol	iwnctryshp(xzgaugfqcc) = ikrkwrfglo semrhutrxv (tsnfmcgtzd ) View more	Positive	01 Nov 2017
				Placebo	iwnctryshp(zmfavwlfkv) = hfsdnhgfvo qtiuqbilwp (jqtprswhsb ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis